NVCR - Novocure: Why It's Still Worth Buying

• Yesterday, Novocure's stock price made a huge jump of 50% because of an update of its LUNAR study.
• We look at the history of the company and the key people.
• Novocure already has 3 FDA approvals, 2 for glioblastoma and 1 for mesothelioma, but its total addressable market is much bigger.
• We look at how its TTF technology works and what it means for Novocure's total addressable market.
• Why exactly the stock price has shot up but there is still upside left.

For further details see: